Browsing by Author McCarthy, Caitlyn
Showing results 1 to 3 of 3
| Issue Date | Title | Author(s) |
| 2022 | Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial | Avihingsanon1, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn |
| 2022-06 | Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial | Avihingsanon, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn; Mugyenyi, Peter |
| 2025-05-02 | Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites | Kityo, Cissy; McCarthy, Caitlyn; Koenig, Serena P; Hughes, Michael D; Wallis, Carole L; Tsikhutsu, Isaac; Munyanga, Cornelius; Mwelase, Noluthando; Schalkwyk, Marije Van; Marc, Jean Bernard; Mponda, Kelvin; Dawson, Rodney; Some, Fatma F; Mohapi, Lerato; Flexner, Charles |
